rucaparib,abiraterone,enzalutamide
astellas,pfizer,clovis oncology
['rucaparib', 'prostate', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'triton3']
late breaking at #gu23: in triton3, a randomized trial involving men with metastatic prostate cancer with a dna-repair defect, rucaparib was associated with longer progression-free survival than a control medication (11.2 vs. 6.4 months). | 